{"id":"SCR-004","title":"候選投資研究進度","chart":"matrix","metric":"必要研究項目完成率（%）","secondary":"待覆核證據數（項）","x":"研究維度","y":"必要研究項目完成率（%）","sample":true,"as_of":"2026-10-16","symbol":"0700.HK","period":"1Y","benchmark":"HSI","symbol_name":"騰訊控股","benchmark_name":"恒生指數","currency":"HKD","period_start":"2025-10-16","period_end":"2026-10-16","summary":[{"key":"max","label":"最高項：盈利模式","value":95.1,"unit":"%"},{"key":"min","label":"最低項：財務風險","value":82.5,"unit":"%"},{"key":"average","label":"平均","value":90.3,"unit":"%"},{"key":"count","label":"項目數","value":5,"unit":"項"}],"panels":[{"title":"候選研究進度矩陣","subtitle":"必要研究項目完成率（%）","chart":"matrix","labels":["盈利模式","估值依據","財務風險","催化事件","反面論點"],"series":[{"name":"必要研究項目完成率（%）","data":[[0,0,97.0],[1,0,88.3],[2,0,84.1],[3,0,89.8],[4,0,94.0],[0,1,91.4],[1,1,87.2],[2,1,81.5],[3,1,83.8],[4,1,84.8],[0,2,99.1],[1,2,94.1],[2,2,85.4],[3,2,99.9],[4,2,100.0],[0,3,97.2],[1,3,90.3],[2,3,84.5],[3,3,97.2],[4,3,98.1],[0,4,90.6],[1,4,89.2],[2,4,77.2],[3,4,84.6],[4,4,87.7]],"unit":"%"}],"columns":[],"rows":[],"x_labels":["盈利模式","估值依據","財務風險","催化事件","反面論點"],"y_labels":["示例同業甲","示例同業乙","示例同業丙","示例同業丁","示例同業戊"],"calendar_range":"","x_name":"研究維度","y_name":"必要研究項目完成率（%）","unit":"%"},{"title":"已確認證據與日期","subtitle":"待覆核證據數（項）","chart":"bar","labels":["盈利模式","估值依據","財務風險","催化事件","反面論點"],"series":[{"name":"待覆核證據數（項）","data":[28,9,15,13,17],"unit":"項","axis":"left"}],"columns":[],"rows":[],"x_labels":["盈利模式","估值依據","財務風險","催化事件","反面論點"],"y_labels":[],"calendar_range":"","x_name":"研究維度","y_name":"待覆核證據數（項）","unit":"項"},{"title":"未解決疑點與下一步","subtitle":"必要研究項目完成率（%） 與 待覆核證據數（項）","chart":"table","labels":["盈利模式","估值依據","財務風險","催化事件","反面論點"],"series":[{"name":"必要研究項目完成率（%）","data":[95.1,89.8,82.5,91.1,92.9],"unit":"%"}],"columns":[{"key":"label","label":"研究維度"},{"key":"value","label":"必要研究項目完成率（%）"},{"key":"comparison","label":"待覆核證據數（項）"},{"key":"date","label":"資料日期（示例）"}],"rows":[{"label":"盈利模式","value":95.1,"comparison":28,"date":"2026-10-16"},{"label":"估值依據","value":89.8,"comparison":9,"date":"2026-10-16"},{"label":"財務風險","value":82.5,"comparison":15,"date":"2026-10-16"},{"label":"催化事件","value":91.1,"comparison":13,"date":"2026-10-16"},{"label":"反面論點","value":92.9,"comparison":17,"date":"2026-10-16"}],"x_labels":["盈利模式","估值依據","財務風險","催化事件","反面論點"],"y_labels":[],"calendar_range":"","x_name":"研究維度","y_name":"資料明細","unit":""}],"rows":[{"label":"盈利模式","value":95.1,"comparison":28,"date":"2026-10-16"},{"label":"估值依據","value":89.8,"comparison":9,"date":"2026-10-16"},{"label":"財務風險","value":82.5,"comparison":15,"date":"2026-10-16"},{"label":"催化事件","value":91.1,"comparison":13,"date":"2026-10-16"},{"label":"反面論點","value":92.9,"comparison":17,"date":"2026-10-16"}],"columns":[{"key":"label","label":"研究維度"},{"key":"value","label":"必要研究項目完成率（%）"},{"key":"comparison","label":"待覆核證據數（項）"},{"key":"date","label":"資料日期（示例）"}]}